The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
- Author:
Jong Hyun CHOI
1
;
Juwhan CHOI
;
Sang Mi CHUNG
;
Jee Youn OH
;
Young Seok LEE
;
Kyung Hoon MIN
;
Gyu Young HUR
;
Jae Jeong SHIM
;
Kyung Ho KANG
;
Hyun Kyung LEE
;
Sung Yong LEE
Author Information
- Publication Type:Original Article
- Keywords: Carcinoma, Non-Small-Cell Lung; Chemotherapy; Docetaxel; Treatment Outcome; Safety; Therapeutics; Aged; Lung Neoplasms; Carcinoma, Squamous Cell
- MeSH: Aged; Appointments and Schedules; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Study; Disease-Free Survival; Drug Therapy; Epithelial Cells; Humans; Incidence; Lung Neoplasms; Lung; Neutropenia; Treatment Outcome
- From:Tuberculosis and Respiratory Diseases 2019;82(3):211-216
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. METHODS: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. RESULTS: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. CONCLUSION: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.
